Why should we use multifunctional neuroprotective and neurorestorative drugs for Parkinson's disease?
暂无分享,去创建一个
Werner J Geldenhuys | Cornelis J Van der Schyf | W. Geldenhuys | C. J. Van der Schyf | M. Youdim | Moussa B H Youdim | C. J. van der Schyf
[1] Craig Mallinckrodt,et al. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. , 2002, The Journal of clinical psychiatry.
[2] M. Youdim,et al. Novel multifunctional neuroprotective iron chelator‐monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP‐induced striatal dopamine depletion , 2005, Journal of neurochemistry.
[3] K. Lyseng-Williamson,et al. Memantine , 2012, PharmacoEconomics.
[4] M. Youdim,et al. Neuroprotection via pro‐survival protein kinase C isoforms associated with Bcl‐2 family members , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[5] R. Duvoisin,et al. Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B. , 1985, European journal of pharmacology.
[6] J. Bloomquist,et al. Selective effects of cyclodiene insecticides on dopamine release in mammalian synaptosomes. , 2002, Toxicology and applied pharmacology.
[7] W. Coetzee,et al. Characterization of NGP 1-01, an aromatic polycyclic amine, as a calcium antagonist. , 1986, Pharmacological research communications.
[8] R. Uitti,et al. Familial Parkinson's Disease: Possible Role of Environmental Factors , 1987, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[9] M. Piercey. Pharmacology of Pramipexole, a Dopamine D3-Preferring Agonist Useful in Treating Parkinson's Disease , 1998, Clinical neuropharmacology.
[10] A. Lang,et al. Parkinson's disease. First of two parts. , 1998, The New England journal of medicine.
[11] B. Shukitt-Hale,et al. Reversing the deleterious effects of aging on neuronal communication and behavior: beneficial properties of fruit polyphenolic compounds. , 2005, The American journal of clinical nutrition.
[12] Jack J. Chen,et al. Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease. , 2006, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[13] D. Lahiri,et al. Metal and inflammatory targets for Alzheimer's disease. , 2004, Current drug targets.
[14] Richard Morphy,et al. From magic bullets to designed multiple ligands. , 2004, Drug discovery today.
[15] M. Youdim,et al. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases. , 2005, Bioorganic & medicinal chemistry.
[16] Wei Huang,et al. Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease. , 2002, Journal of medicinal chemistry.
[17] P. Riederer,et al. MAO-B inhibitors: multiple roles in the therapy of neurodegenerative disorders? , 2000, Parkinsonism & related disorders.
[18] Houeto Jean-Luc. [Parkinson's disease]. , 2022, La Revue du praticien.
[19] Piercey Mf. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. , 1998 .
[20] M. Schwarzschild,et al. Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists. , 2003, Bioorganic & medicinal chemistry.
[21] M. Naoi,et al. (−)‐Deprenyl Protects Human Dopaminergic Neuroblastoma SH‐SY5Y Cells from Apoptosis Induced by Peroxynitrite and Nitric Oxide , 1998, Journal of neurochemistry.
[22] J. Lehár,et al. Multi-target therapeutics: when the whole is greater than the sum of the parts. , 2007, Drug discovery today.
[23] W. Tatton,et al. Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B , 2003, Journal of Neural Transmission.
[24] C. J. Van der Schyf,et al. Monoamine oxidase B inhibition and neuroprotection , 2003, Neurology.
[25] Q. Guo,et al. Studies on protective mechanisms of four components of green tea polyphenols against lipid peroxidation in synaptosomes. , 1996, Biochimica et biophysica acta.
[26] W. Geldenhuys,et al. Multifunctional neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutamatergic action for neurodegenerative diseases , 2006, Expert opinion on investigational drugs.
[27] A. Lang,et al. Parkinson's disease. Second of two parts. , 1998, The New England journal of medicine.
[28] J. Saura,et al. Differential age-related changes of mao-a and mao-b in mouse brain and pe peripheral organs , 1994, Neurobiology of Aging.
[29] Jack J. Chen,et al. Clinical Pharmacology of Rasagiline: A Novel, Second‐Generation Propargylamine for the Treatment of Parkinson Disease , 2005, Journal of clinical pharmacology.
[30] W. Geldenhuys,et al. Screening of novel pentacyclo-undecylamines for neuroprotective activity. , 2003, European journal of pharmacology.
[31] S. Mandel,et al. Green tea catechins as brain-permeable, natural iron chelators-antioxidants for the treatment of neurodegenerative disorders. , 2006, Molecular nutrition & food research.
[32] G. Lescoat,et al. Antioxidant and iron-chelating activities of the flavonoids catechin, quercetin and diosmetin on iron-loaded rat hepatocyte cultures. , 1993, Biochemical pharmacology.
[33] A. Korczyn,et al. Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease , 1992, Journal of neural transmission. Parkinson's disease and dementia section.
[34] R. Hider,et al. Metal chelation of polyphenols. , 2001, Methods in enzymology.
[35] J. Friedman,et al. Double‐blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients , 2004, Movement disorders : official journal of the Movement Disorder Society.
[36] M. Youdim,et al. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases , 2005, Mechanisms of Ageing and Development.
[37] M. Rogawski,et al. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. , 2006, CNS drug reviews.
[38] M. Youdim,et al. Effect of TV3326, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression , 2002, Psychopharmacology.
[39] J. Saura,et al. Biphasic and Region-Specific MAO-B Response to Aging in Normal Human Brain , 1997, Neurobiology of Aging.
[40] C. Parsons,et al. Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist—a review of preclinical data , 1999, Neuropharmacology.
[41] R. Hider,et al. Metal Chelation of Polyphenols , 2001 .
[42] S. Mandel,et al. Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives , 2005, Brain Research Reviews.
[43] J. Hartmann,et al. NGP1-01 is a Brain-permeable Dual Blocker of Neuronal Voltage- and Ligand-operated Calcium Channels , 2006, Neurochemical Research.
[44] R. Prediger,et al. Caffeine reverses age-related deficits in olfactory discrimination and social recognition memory in rats Involvement of adenosine A1 and A2A receptors , 2005, Neurobiology of Aging.
[45] Neal Castagnoli,et al. 8-(3-Chlorostyryl)caffeine May Attenuate MPTP Neurotoxicity through Dual Actions of Monoamine Oxidase Inhibition and A2A Receptor Antagonism* , 2002, The Journal of Biological Chemistry.
[46] M. Merello,et al. Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study. , 1999, Clinical neuropharmacology.
[47] A. de Mendonça,et al. Does caffeine intake protect from Alzheimer's disease? , 2002, European journal of neurology.
[48] M. Youdim,et al. Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats , 2004, Neuropharmacology.
[49] J. Connor,et al. Iron, brain ageing and neurodegenerative disorders , 2004, Nature Reviews Neuroscience.
[50] W. Geldenhuys,et al. Multifunctional neuroprotective drugs for the treatment of cognitive and movement impairment disorders, including Alzheimer's and Parkinson's diseases , 2006 .
[51] S. Mandel,et al. Reduction of iron‐regulated amyloid precursor protein and β‐amyloid peptide by (–)‐epigallocatechin‐3‐gallate in cell cultures: implications for iron chelation in Alzheimer's disease , 2006, Journal of neurochemistry.
[52] Nir Giladi,et al. Rasagiline Mesylate, a New Mao-B Inhibitor for the Treatment of Parkinson's Disease: A Double-Blind Study as Adjunctive Therapy to Levodopa , 2000, Clinical neuropharmacology.
[53] M. Ikeda,et al. Effects of duloxetine, a new serotonin and norepinephrine uptake inhibitor, on extracellular monoamine levels in rat frontal cortex. , 1995, The Journal of pharmacology and experimental therapeutics.
[54] Richard Morphy,et al. Designed Multiple Ligands. An Emerging Drug Discovery Paradigm , 2006 .
[55] B. Schoenberg. Environmental Risk Factors for Parkinson's Disease: The Epidemiologic Evidence , 1987, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[56] T. Amit,et al. Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro , 2007, Journal of neurochemistry.
[57] S. Mandel,et al. Neuroprotection and neurorescue against Aβ toxicity and PKC‐dependent release of non‐amyloidogenic soluble precursor protein by green tea polyphenol (‐)‐epigallocatechin‐3‐gallate , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[58] M. Youdim,et al. The FASEB Journal express article 10.1096/fj.05-3794fje. Published online September 7, 2005. , 2022 .
[59] F. Gonzalez,et al. Parkinson's disease, pesticides and individual vulnerability. , 2004, Trends in pharmacological sciences.
[60] Y. Agid,et al. Treatment of End-of-Dose Wearing-Off in Parkinson’s Disease: Stalevo® (Levodopa/Carbidopa/Entacapone) and Levodopa/DDCI Given in Combination with Comtess®/Comtan® (Entacapone) Provide Equivalent Improvements in Symptom Control Superior to That of Traditional Levodopa/DDCI Treatment , 2005, European Neurology.
[61] P. Jenner,et al. Dopamine reuptake inhibition and failure to evoke dyskinesia in MPTP-treated primates. , 2002, European journal of pharmacology.
[62] C. Olanow. Neuroprotective Strategies in Parkinson’s Disease , 2009 .
[63] J. Langston,et al. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. , 2004, Archives of neurology.
[64] M. Youdim,et al. Attenuation of MPTP‐induced dopaminergic neurotoxicity by TV3326, a cholinesterase‐monoamine oxidase inhibitor , 2003, Journal of neurochemistry.
[65] Fabrizio Gardoni,et al. New targets for pharmacological intervention in the glutamatergic synapse. , 2006, European journal of pharmacology.
[66] David Morgan,et al. Green Tea Epigallocatechin-3-Gallate (EGCG) Modulates Amyloid Precursor Protein Cleavage and Reduces Cerebral Amyloidosis in Alzheimer Transgenic Mice , 2005, The Journal of Neuroscience.
[67] M. Youdim,et al. Rasagiline [N‐propargyl‐1R(+)‐aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B , 2001, British journal of pharmacology.
[68] W. Geldenhuys,et al. Synthesis and biological evaluation of pentacyclo[5.4.0.02,6.03,10.05,9]undecane derivatives as potential therapeutic agents in Parkinson's disease , 2004 .
[69] M. Kaps,et al. Neuroprotective effects of MK-801 in different rat stroke models for permanent middle cerebral artery occlusion: adverse effects of hypothalamic damage and strategies for its avoidance. , 2003, Stroke.
[70] S. Mandel,et al. Multifunctional Activities of Green Tea Catechins in Neuroprotection , 2005, Neurosignals.
[71] Patrik Brundin,et al. Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. , 2002, Nature reviews. Neuroscience.
[72] M. Küçük,et al. Reduction of Edema and Infarction by Memantine and MK-801 After Focal Cerebral Ischaemia and Reperfusion in Rat , 2000, Acta Neurochirurgica.
[73] S. Starkman,et al. Potential role of neuroprotective agents in the treatment of patients with acute ischemic stroke , 2003, Current treatment options in neurology.
[74] M. Youdim,et al. Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness , 2006, British journal of pharmacology.
[75] M. Youdim. The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30. , 2006, Current Alzheimer research.
[76] W. Geldenhuys,et al. NGP1-01, a lipophilic polycyclic cage amine, is neuroprotective in focal ischemia , 2005, Neuroscience Letters.
[77] A. Markham,et al. Pramipexole. A review of its use in the management of early and advanced Parkinson's disease. , 1998, Drugs & aging.
[78] E. Hall,et al. Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons , 1996, Brain Research.
[79] T. Amit,et al. The neuroprotective effect of Activin A and B: implication for neurodegenerative diseases , 2007, Journal of neurochemistry.
[80] D. Souza,et al. Neuroprotection by caffeine and adenosine A2A receptor blockade of β‐amyloid neurotoxicity , 2003, British journal of pharmacology.
[81] C. Olanow,et al. Neuroprotection in Parkinson's disease: Clinical trials , 2003, Annals of neurology.
[82] T. Odergren,et al. Animal models of stroke: do they have value for discovering neuroprotective agents? , 2003, Trends in pharmacological sciences.
[83] W. Tatton,et al. (-)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase. , 1996, Journal of neural transmission. Supplementum.
[84] M. Yahr,et al. Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys. , 1984, European journal of pharmacology.
[85] M. Naoi,et al. N-Propargylamine protects SH-SY5Y cells from apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, through stabilization of mitochondrial membrane and induction of anti-apoptotic Bcl-2 , 2005, Journal of Neural Transmission.
[86] B. Szende,et al. (-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties. , 2004, Neurotoxicology.
[87] S. Mandel,et al. Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases. , 2004, The Journal of nutritional biochemistry.
[88] P. Riederer,et al. Monoamine oxidase-B inhibition in Alzheimer's disease. , 2004, Neurotoxicology.
[89] M. Youdim,et al. Novel Neuroprotective Mechanism of Action of Rasagiline Is Associated with Its Propargyl Moiety: Interaction of Bcl‐2 Family Members with PKC Pathway , 2005, Annals of the New York Academy of Sciences.
[90] Jerry J Buccafusco,et al. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. , 2005, Trends in pharmacological sciences.
[91] F. Crews,et al. TNFα potentiates glutamate neurotoxicity by inhibiting glutamate uptake in organotypic brain slice cultures: neuroprotection by NFκB inhibition , 2005, Brain Research.
[92] D. Wong,et al. LY227942, an inhibitor of serotonin and norepinephrine uptake: biochemical pharmacology of a potential antidepressant drug. , 1988, Life sciences.
[93] M. Youdim,et al. Therapeutic targets and potential of the novel brain‐ permeable multifunctional iron chelator–monoamine oxidase inhibitor drug, M‐30, for the treatment of Alzheimer's disease 1 , 2007, Journal of neurochemistry.
[94] W. Geldenhuys,et al. Structure-activity relationships of pentacycloundecylamines at the N-methyl-d-aspartate receptor. , 2007, Bioorganic & medicinal chemistry.
[95] J. Buccafusco,et al. CNS Targets for multi-functional drugs in the treatment of Alzheimer’s and Parkinson’s diseases , 2005, Journal of Neural Transmission.
[96] E. Bézard,et al. Neuroprotective strategies for Parkinson's disease: conceptual limits of animal models and clinical trials. , 2004, Trends in pharmacological sciences.
[97] R. Levy,et al. Tolerability, Safety, Pharmacodynamics, and Pharmacokinetics of Rasagiline: A Potent, Selective, and Irreversible Monoamine Oxidase Type B Inhibitor , 2004, Pharmacotherapy.
[98] J. Kemp,et al. NMDA receptor pathways as drug targets , 2002, Nature Neuroscience.
[99] N. Cutler,et al. Recent Developments in the Drug Treatment of Alzheimer’s Disease , 1999, Drugs & aging.
[100] S. Gullans,et al. Drug discovery targeted to the Alzheimer’s APP mRNA 5′-untranslated region , 2007, Journal of Molecular Neuroscience.
[101] B. Szende,et al. Pharmacological aspects of (-)-deprenyl. , 2004, Current medicinal chemistry.
[102] M. Chevion,et al. Protective effects of tea polyphenols against oxidative damage to red blood cells. , 1997, Biochemical pharmacology.
[103] Andrea Mattevi,et al. Three-dimensional structure of human monoamine oxidase A (MAO A): relation to the structures of rat MAO A and human MAO B. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[104] J. Jankovic,et al. Prevention and restoration of lactacystin‐induced nigrostriatal dopamine neuron degeneration by novel brain‐permeable iron chelators , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[105] S. Mandel,et al. Green tea polyphenol (–)‐epigallocatechin‐3‐gallate induces neurorescue of long‐term serum‐deprived PC12 cells and promotes neurite outgrowth , 2005, Journal of neurochemistry.
[106] P. Riederer,et al. Selegiline is neuroprotective in primary brain cultures treated with 1-methyl-4-phenylpyridinium. , 1996, European journal of pharmacology.
[107] S. Minoshima,et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1998, Nature.
[108] T. Suuronen,et al. Protective effect of L-deprenyl against apoptosis induced by okadaic acid in cultured neuronal cells. , 2000, Biochemical pharmacology.
[109] M. Youdim,et al. Rasagiline: Neurodegeneration, neuroprotection, and mitochondrial permeability transition , 2005, Journal of neuroscience research.
[110] M. Tabata,et al. Effects of pH and Metal Ions on Antioxidative Activities of Catechins , 2001, Bioscience, biotechnology, and biochemistry.
[111] S. Mandel,et al. Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism , 2007, Neurobiology of Disease.
[112] K. Perry,et al. Deprenyl antagonizes acute lethality of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. , 1988, The Journal of pharmacology and experimental therapeutics.
[113] M. Limburg,et al. Calcium antagonists for acute ischemic stroke. , 2000, The Cochrane database of systematic reviews.
[114] M. Youdim,et al. Novel multifunctional neuroprotective iron chelator‐monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition , 2005, Journal of neurochemistry.
[115] A. Siderowf,et al. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. , 2004, Archives of neurology.
[116] P. Lipton,et al. Ischemic cell death in brain neurons. , 1999, Physiological reviews.